ACTG Announces Graduation of Novel Polyclonal Antibody Therapy SAB-185 to Phase 3 Study in ACTIV-2

<svg width="22" height="13" viewBox="0 0 22 13" fill="none" xmlns="http://www.w3.org/2000/svg"> <path d="M19.9993 1.50781L11.0143 10.4928L2.0293 1.50781" stroke="#2A3741" stroke-width="3"/>

<svg width="22" height="13" viewBox="0 0 22 13" fill="none" xmlns="http://www.w3.org/2000/svg"> <path d="M19.9993 1.50781L11.0143 10.4928L2.0293 1.50781" stroke="#2A3741" stroke-width="3"/>

<svg width="22" height="13" viewBox="0 0 22 13" fill="none" xmlns="http://www.w3.org/2000/svg"> <path d="M19.9993 1.50781L11.0143 10.4928L2.0293 1.50781" stroke="#2A3741" stroke-width="3"/>

<svg width="22" height="13" viewBox="0 0 22 13" fill="none" xmlns="http://www.w3.org/2000/svg"> <path d="M19.9993 1.50781L11.0143 10.4928L2.0293 1.50781" stroke="#2A3741" stroke-width="3"/>

<svg width="22" height="13" viewBox="0 0 22 13" fill="none" xmlns="http://www.w3.org/2000/svg"> <path d="M19.9993 1.50781L11.0143 10.4928L2.0293 1.50781" stroke="#2A3741" stroke-width="3"/>